Multiple pathways and indirect molecular targets

The term "Multiple pathways and indirect molecular targets" does not refer to a single biological entity, such as a specific protein or receptor, but is instead a nomenclature used to describe therapeutic agents with complex or poorly defined mechanisms of action. This designation is often applied to drugs that exhibit polypharmacology, where the clinical efficacy is derived from the simultaneous modulation of several distinct signaling pathways rather than a single primary target (Peters, 2013, Nature Reviews Drug Discovery). In many cases, these "indirect" effects may involve systemic physiological changes, such as alterations in metabolic flux, gut microbiota modulation, or immune system priming, which cannot be attributed to a single molecular binding event. For drug developers and biotech analysts, this classification poses significant challenges in terms of target validation, dose-response modeling, and the identification of specific safety biomarkers. Consequently, this entry is considered a placeholder or a non-specific classification rather than a valid, discrete therapeutic target for structured pharmacological databases.

Other names

Indirect molecular targetsMulti-target mechanismPolypharmacologyNon-specific mechanism of actionSystemic modulation

Modulation of multiple cellular signaling pathways and indirect physiological responses rather than binding to a single primary protein target.